Metalloproteinase inhibitor prevents hepatic injury in endotoxemic mice

European Journal of Pharmacology

Volumn 341, Issue 1, 1998, Pages 105-110

  Murakami, Kazuki ^a   Kobayashi, Fujio ^a   Ikegawa, Ruriko ^a   Koyama, Mamoru ^a   Shintani, Nahoko ^a   Yoshida, Tomohiro ^a   Nakamura, Norifumi ^a   Kondo, Takao ^a  

^a Pharmacology Laboratories   (Japan)

Author keywords

GI 129471; Hepatic injury; Lipopolysaccharide; Metalloproteinase inhibitor; TNF (Tumor necrosis factor )

Indexed keywords

[4 (N HYDROXYAMINO) 2 ISOBUTYL 3 (PHENYLTHIOMETHYL)SUCCINYL]PHENYLALNINE N METHYLAMIDE; GALACTOSAMINE; LIPOPOLYSACCHARIDE; METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOTOXEMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER INJURY; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

ANIMALS; ENDOTOXEMIA; HUMANS; LIVER; MALE; METALLOENDOPEPTIDASES; MICE; PHENYLALANINE; PROTEASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 0032472320     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01448-9     Document Type: Article

References (29)

1. Aggarwal B.B., Kohr W.J., Hass P.E., Moffat B., Spencer S.A., Henzel W.J., Bringman T.S., Nedwin G.E., Goeddel D.V., Harkins R.N. Human tumor necrosis factor. Production, purification, and characterization. J. Biol. Chem. 260:1985;2345-2354.
2. Arthur M.J.P. Role of Ito cells in the degradation of matrix in liver. J. Gastroenterol. Hepatol. 10:1995;S57-S62.
3. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
4. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., Castner B.J., Stocking K.L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K.A., Gerhart M., Davis R., Fitzner J.N., Johnson R.S., Paxton R.J., March C.J., Cerretti D.P. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 385:1997;729-733.
5. Calandra T., Baumgartner J.D., Grau G.E., Wu M.M., Lambert P.H., Schellekens J., Verhoef J., Glauser M.P. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J. Infect. Dis. 161:1990;982-987.
6. Campion, C., Dickens, J.P., Crimmin, M.J., 1990. Patent WO 90/05719, British Biotechnology.
7. Damas P., Reuter A., Gysen P., Demonty J., Lamy M., Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care. Med. 17:1989;975-978.
8. Fong Y., Tracey K.J., Moldawer L.L., Hesse D.G., Manogue K.B., Kenney J.S., Lee A.T., Kuo G.C., Allison A.C., Lowry S.F., Cerami A. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J. Exp. Med. 170:1989;1627-1633.
9. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L.M., Woolley K. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature. 370:1994;555-557.
10. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J.M., Crimmin M., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R., Gordon J.L., Leber T.M., Mangan M., Miller K., Nayee P., Owen K., Patel S., Thomas W., Wells G., Wood L.M., Woolley K. Matrix metalloproteinases and processing of pro-TNF-α J. Leukocyte Biol. 57:1995;774-777.
11. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83:1995;793-802.
12. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1995;1777-1783.
13. Kriegler M., Perez C., DeFay K., Albert I., Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell. 53:1988;45-53.
14. McGeehan G.M., Becherer J.D., Bast R.J., Boyer C.M., Champion B., Connolly K.M., Conway J.G., Furdon P., Karp S., Kidao S., McElroy A.B., Nichols J., Pryzwansky K.M., Schoenen F., Sekut L., Truesdale A., Verghese M., Warner J., Ways J.P. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature. 370:1994;558-561.
15. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., Cerami A., Wolff S.M., Wilmore D.W. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318:1988;1481-1486.
16. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., Torrance D.S., Otten E.C., Greenstreet T., Weerawarna K., Kronheim S.R., Petersen M., Gerhart M., Kozlosky C.J., March C.J., Black R.A. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 370:1994;218-220.
17. Moss M.L., Catherine Jin S.-L., Milla M.E., Burkhart W., Carter H.L., Chen W.J., Clay W.C., Didsbury J.R., Hassler D., Hoffman C.R., Kost T.A., Lambert M.H., Leesnitzer M.A., McCauley P., McGeehan G., Mitchell J., Moyer M., Pahel G., Rocque W., Overton L.K., Schoenen F., Seaton T., Su J.L., Warner J., Willard D., Becherer J.D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α Nature. 385:1997;733-736.
18. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
19. Ogasawara J., Watanabe F.R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
20. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A., Wiegmann K., Ohashi P.S., Kronke M., Mak T.W. Mice deficient for the 55 kDa tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73:1993;457-467.
21. Remick D.G., Kunkel R.G., Larrick J.W., Kunkel S.L. Acute in vivo effects of human recombinant tumor necrosis factor. Lab. Invest. 56:1987;583-590.
22. Solorzano C.C., Ksontini R., Pruitt J.H., Hess P.J., Edwards P.D., Kaibara A., Abouhamze A., Auffenberg T., Galardy R.E., Vauthey J.N., Copeland E.M. III, Edwards C.K. III, Lauwers G.Y., Clare-Salzler M., MacKay S.L.D., Moldawer L.L., Lazarus D.D. Involvemant of 26 kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J. Immunol. 158:1997;414-419.
23. Tiegs G., Wolter M., Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 38:1989;627-631.
24. Tracey K.J., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell Biol. 9:1993;317-343.
25. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., Hariri R.J., Fahey T.J. III, Zentella A., Albert J.D., Shires G.T., Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470-474.
26. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., Lowry S.F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
27. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10:1992;411-452.
28. Wang P., Ayala A., Ba Z.F., Zhou M., Perrin M.M., Chaudry I.H. Tumor necrosis factor-α produces hepatocellular dysfunction despite normal cardiac output and hepatic microcirculation. Am. J. Physiol. 265:1993;G126-G132.
29. Wang J.H., Redmond H.P., Watson R.W., Bouchier H.D. Role of lipopolysaccharide and tumor necrosis factor-α in induction of hepatocyte necrosis. Am. J. Physiol. 269:1995;G297-G304.